FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135121504> ?p ?o ?g. }

• W2135121504 endingPage "2039" @default.
• W2135121504 startingPage "2022" @default.
• W2135121504 abstract "Background: Tramadol is widely prescribed, even to the eldest patients. Although age-related differences in pharmacologic responsiveness are to be expected, the pharmacodynamic and pharmacokinetic (PK) properties of tramadol have not been systematically compared between patients of various ages. Objective: The aim of this study was to explore the effectiveness, PK properties, and safety profile of 2 galenic tramadol formulations in 3 similarly sized age groups with malignant and nonmalignant pain of moderate to severe intensity. Methods: This prospective, age-group-controlled study was conducted at the ambulatory pain clinic of the Landeskrankenhaus Kärnten, Klagenfurt, Austria. Male and female adults with malignant and nonmalignant pain of moderate to severe intensity were eligible. Patients were stratified into similarly sized age groups, as follows: ≥75, 65-<75, and <65 years. Patients first received the immediate-release galenic formulation of tramadol (tramadol IR) until steady state was achieved, followed by the sustained-release formulation (tramadol SR) until steady state. Serum concentrations of tramadol and its active metabolite (O-desmethyl-tramadol [M1]) were measured using gas chromatography to estimate the age-related PK handling of the analgesic drug. Three validated scales were used to measure pain intensity during the study: a 100-mm visual analog scale (VAS), an 11-point numeric analog scale (NAS), and a 4-point verbal rating scale (VRS). Tolerability was assessed by evaluating daily answers about the potential occurrence of adverse events (and respective details such as type and severity) from baseline until the end of the observation period. Results: A total of 100 patients were enrolled (58 women, 42 men; mean [SD] age, 65.2 [15.0] years; ≥75, 30 patients; 65-<75, 31 patients; and <65 years, 39 patients). Predominant causes of pain were neoplasms (27.4% of causes) and injury and other external causes (20.8%), and diseases of the musculoskeletal and connective-tissues systems (19.8%). Fifty-five patients completed the study and provided all data as planned. Mean (SEM) steady-state tramadol IR doses were 250 (20.2), 277 (39.8), and 325 (33.1) mg/d in patients aged ≥75, 65-<75, and 65 years, respectively (P = NS); tramadol SR, 278 (27.5), 306 (39.7), and 340 (35.1) mg/d (P = NS). Serum concentrations of tramadol and M1 were statistically similar across all 3 age groups. Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001). Pain intensity before and improvements during both treatment phases were similar across all 3 age groups. Results: for pain intensity on the VRS also did not find age-related differences. The predominant adverse effects were nausea (27.0% of patients), dizziness and giddiness (18.0%), and malaise and fatigue (15.0%); no significant differences in adverse events were found between age groups. Conclusions: The fate of tramadol and its active metabolite, and their clinical effects, have been examined here for the first time in a prospective cohort study, which compared patients aged <65 years, 65-<75 years, and ≥75 years. In contrast to expecta tions, it was concluded that tramadol IR and tramadol SR were both generally well tolerated and effective in the treatment of moderate to severe pain in any of the 3 age groups in these patients. Although the eldest group of patients consumed, on average, 20% less tramadol (P = NS) than the youngest group, the PK properties of both drugs were not changed when given to elderly patients." @default.
• W2135121504 created "2016-06-24" @default.
• W2135121504 creator A5000478520 @default.
• W2135121504 creator A5000800817 @default.
• W2135121504 creator A5046861299 @default.
• W2135121504 creator A5053267229 @default.
• W2135121504 creator A5069701113 @default.
• W2135121504 creator A5079231638 @default.
• W2135121504 date "2006-12-01" @default.
• W2135121504 modified "2023-09-23" @default.
• W2135121504 title "Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: A prospective, age-group-controlled study" @default.
• W2135121504 cites W139047705 @default.
• W2135121504 cites W1970515047 @default.
• W2135121504 cites W1976588412 @default.
• W2135121504 cites W1981072846 @default.
• W2135121504 cites W1981629756 @default.
• W2135121504 cites W2003438674 @default.
• W2135121504 cites W2007440728 @default.
• W2135121504 cites W2013317282 @default.
• W2135121504 cites W2031737952 @default.
• W2135121504 cites W2033769607 @default.
• W2135121504 cites W2037565846 @default.
• W2135121504 cites W2041320351 @default.
• W2135121504 cites W2042443179 @default.
• W2135121504 cites W2046441247 @default.
• W2135121504 cites W2047076695 @default.
• W2135121504 cites W2049287441 @default.
• W2135121504 cites W2062420546 @default.
• W2135121504 cites W2065776872 @default.
• W2135121504 cites W2085252098 @default.
• W2135121504 cites W2095574179 @default.
• W2135121504 cites W2128168522 @default.
• W2135121504 cites W2151802930 @default.
• W2135121504 cites W2164017860 @default.
• W2135121504 cites W2406226950 @default.
• W2135121504 cites W4235032443 @default.
• W2135121504 cites W42618186 @default.
• W2135121504 cites W79691373 @default.
• W2135121504 doi "https://doi.org/10.1016/j.clinthera.2006.12.007" @default.
• W2135121504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17296459" @default.
• W2135121504 hasPublicationYear "2006" @default.
• W2135121504 type Work @default.
• W2135121504 sameAs 2135121504 @default.
• W2135121504 citedByCount "25" @default.
• W2135121504 countsByYear W21351215042012 @default.
• W2135121504 countsByYear W21351215042013 @default.
• W2135121504 countsByYear W21351215042014 @default.
• W2135121504 countsByYear W21351215042015 @default.
• W2135121504 countsByYear W21351215042016 @default.
• W2135121504 countsByYear W21351215042017 @default.
• W2135121504 countsByYear W21351215042018 @default.
• W2135121504 countsByYear W21351215042019 @default.
• W2135121504 countsByYear W21351215042021 @default.
• W2135121504 countsByYear W21351215042022 @default.
• W2135121504 crossrefType "journal-article" @default.
• W2135121504 hasAuthorship W2135121504A5000478520 @default.
• W2135121504 hasAuthorship W2135121504A5000800817 @default.
• W2135121504 hasAuthorship W2135121504A5046861299 @default.
• W2135121504 hasAuthorship W2135121504A5053267229 @default.
• W2135121504 hasAuthorship W2135121504A5069701113 @default.
• W2135121504 hasAuthorship W2135121504A5079231638 @default.
• W2135121504 hasConcept C111113717 @default.
• W2135121504 hasConcept C112705442 @default.
• W2135121504 hasConcept C126322002 @default.
• W2135121504 hasConcept C14184104 @default.
• W2135121504 hasConcept C188816634 @default.
• W2135121504 hasConcept C197934379 @default.
• W2135121504 hasConcept C2778375690 @default.
• W2135121504 hasConcept C2779777798 @default.
• W2135121504 hasConcept C2780820201 @default.
• W2135121504 hasConcept C35785553 @default.
• W2135121504 hasConcept C42219234 @default.
• W2135121504 hasConcept C71924100 @default.
• W2135121504 hasConceptScore W2135121504C111113717 @default.
• W2135121504 hasConceptScore W2135121504C112705442 @default.
• W2135121504 hasConceptScore W2135121504C126322002 @default.
• W2135121504 hasConceptScore W2135121504C14184104 @default.
• W2135121504 hasConceptScore W2135121504C188816634 @default.
• W2135121504 hasConceptScore W2135121504C197934379 @default.
• W2135121504 hasConceptScore W2135121504C2778375690 @default.
• W2135121504 hasConceptScore W2135121504C2779777798 @default.
• W2135121504 hasConceptScore W2135121504C2780820201 @default.
• W2135121504 hasConceptScore W2135121504C35785553 @default.
• W2135121504 hasConceptScore W2135121504C42219234 @default.
• W2135121504 hasConceptScore W2135121504C71924100 @default.
• W2135121504 hasIssue "12" @default.
• W2135121504 hasLocation W21351215041 @default.
• W2135121504 hasLocation W21351215042 @default.
• W2135121504 hasOpenAccess W2135121504 @default.
• W2135121504 hasPrimaryLocation W21351215041 @default.
• W2135121504 hasRelatedWork W1934667138 @default.
• W2135121504 hasRelatedWork W2026252243 @default.
• W2135121504 hasRelatedWork W2028002420 @default.
• W2135121504 hasRelatedWork W2056546326 @default.
• W2135121504 hasRelatedWork W2090169689 @default.
• W2135121504 hasRelatedWork W2110291759 @default.
• W2135121504 hasRelatedWork W2391863645 @default.
• W2135121504 hasRelatedWork W2766832809 @default.

• next